GAITHERSBURG, Md. – Novavax, Inc. (NASDAQ: NVAX) announced that it has submitted to the Food and Drug Administration (FDA) for an Emergency Use Authorization Amendment for its updated JN.1 COVID-19 vaccine, NVX-CoV2705, for individuals over the age of 12. This move is in response to indications from the FDA, the European Medicines Agency (EMA) and the World Health Organization (WHO), which recommend targeting the JN.1 lineage for the next vaccination season.
The company’s latest vaccine candidate has demonstrated the ability to generate broad cross-neutralizing antibodies against multiple strains, including KP.2 and KP.3 variants. Novavax President and CEO John C. Jacobs emphasized the importance of offering a protein-based vaccine option to potentially increase vaccination rates.
Novavax’s JN.1 vaccine was designed using the company’s recombinant nanoparticle technology to create copies of the SARS-CoV-2 spike protein, combined with the proprietary adjuvant Matrix-M to enhance the immune response. The vaccine is ready to use in liquid form and can be stored at standard refrigeration temperatures, which simplifies its distribution.
The company plans to make doses available in the United States by mid-August, pending FDA authorization and CDC recommendation. Novavax is also in discussions with other global regulatory agencies for approval of its JN.1 COVID-19 vaccine.
Novavax’s press release also highlights non-clinical data demonstrating that the vaccine elicits a broad neutralization response against JN.1 lineage viruses and a number of variants. Furthermore, the vaccine stimulates a Th1-type CD4+ T cell response, which is critical for long-term immunity.
The company’s efforts are part of a broader strategy to address the evolving challenge of COVID-19 and its variants, with the goal of providing an alternative to currently available mRNA vaccines. Novavax’s approach to vaccine development focuses on protein-based formulations, which could offer different immunogenic profiles than other types of vaccines.
As the COVID-19 pandemic continues to pose a threat to global health, Novavax’s vaccine introduction represents a proactive measure to anticipate and combat circulating and future strains of the virus. The company’s willingness to distribute the vaccine once it gets the regulatory green light underlines its commitment to contributing to the global vaccination effort.
In other recent news, Novavax is awaiting approval from the US Food and Drug Administration (FDA) to release its COVID-19 vaccine, designed to target the JN.1 variant. The company has faced challenges bringing its protein-based COVID-19 vaccine to market. However, a recent licensing deal with Sanofi, worth at least $1.2 billion, provided a significant boost. Nonetheless, Novavax expects revenue of between $400 million and $600 million for 2024, a notable decline from $983.7 million in 2023.
In a related development, Pfizer, BioNTech, Moderna and Novavax announced that their latest COVID-19 vaccines show promising results against new subvariants. Pfizer and BioNTech, along with Moderna, are ready to provide updated vaccines immediately upon approval. Novavax expects to be able to supply its vaccine by the fall, pending regulatory approval.
Meanwhile, Shah Capital, a hedge fund that owns about 7.8% of Novavax, has withdrawn its campaign against the re-election of three Novavax directors. The decision follows Novavax’s recent licensing agreement with Sanofi. Despite withdrawing the campaign, Shah Capital argues that Novavax would benefit from having a shareholder representative on the board of directors.
Another note: North American companies, including Novavax, are initiating significant workforce reductions. This trend, which affects several sectors, continues despite the cautiously optimistic economic outlook and uncertainty about future rate cuts by the Federal Reserve.
Insights from InvestingPro
As Novavax, Inc. (NASDAQ: NVAX) prepares to boost global vaccination efforts with its latest COVID-19 vaccine candidate, NVX-CoV2705, the company’s financial and market performance is a backdrop to its scientific efforts. According to InvestingPro, Novavax has been navigating a challenging financial landscape, with a significant liquidity ratio that investors should monitor closely. This situation is reflected in the company’s substantial operating loss over the trailing twelve months of $378.17 million. Additionally, Novavax’s gross profit margin stands at a modest 4.92%, underscoring the financial pressures the company faces as it develops and distributes vaccines.
Despite these financial headwinds, Novavax stock has seen a strong return over the past three months, with a total return of 202.21%. This surge may reflect investor optimism about the company’s potential profitability this year, as analysts predicted. However, the stock’s high volatility, indicated by a one-week total price return of -17.17%, suggests that investors should be prepared for potential market swings.
For those looking for a deeper analysis of Novavax’s financial health and stock performance, InvestingPro offers a number of additional insights. There are currently 12 other InvestingPro tips available, which can be found on the InvestingPro website. Readers interested in taking advantage of these insights can take advantage of a special offer by using the coupon code PRONEWS24 to get an additional 10% discount on an annual or two-year Pro and Pro+ subscription.
This article was generated and translated with the support of artificial intelligence and reviewed by an editor. For further information, please see our T&Cs.
